Showing results (171-180 of 757) with videos related to

Sort By:
Pageof 76
The Lancet. Gastroenterology & Hepatology|June 15, 2026
HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association studyQian Zhang, Eathar Shakweh, Mohmmed Tauseef Sharip, et al.
The Lancet. Gastroenterology & Hepatology|July 3, 2026
Bowel endometriosis: from pathogenesis to clinical managementFabio Barra, Edoardo Giovanni Giannini, Maria Grazia Centurioni, et al.
The Lancet. Gastroenterology & Hepatology|July 2, 2026
The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy studyKyle Staller, Vivek C Goodory, Mais Khasawneh, et al.
The Lancet. Gastroenterology & Hepatology|July 7, 2026
Barrier restoration as a therapeutic strategy for disorders of gut-brain interactionTimmie A Britton, Madhusudan Grover
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
The Lancet. Gastroenterology & Hepatology|July 15, 2026
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trialRohit Loomba, Jacob George, Laurent Castera, et al.
The Lancet. Gastroenterology & Hepatology|July 21, 2026
The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trialMazen Noureddin, Winston Dunn, Rashmee Patil, et al.
The Lancet. Gastroenterology & Hepatology|August 12, 2026
The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalenceShinji Okabayashi, Lindsay Hracs, Joseph W Windsor, et al.
The Lancet. Gastroenterology & Hepatology|August 25, 2026
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trialMasatoshi Kudo, Sadahisa Ogasawara, Ruibao Liu, et al.
The Lancet. Gastroenterology & Hepatology|September 18, 2026
Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association studyLukas Otero Sanchez, Joan Clària, Clélia Galvanin, et al.
Pageof 76